Alimemazine tartrate ................................ 5 mg
Excipients q.s........................................ 1 tablet
Film coated tablet.
Box of 2 blisters x 25 tablets.
Box of 10 blisters x 10 tablets.
Bottle of 200 tablets.
ATC code: R06AD01
Alimemazine is a phenothiazine derivative which is a potent antihistamine and antiserotonin agent. Alimemazine also acts as a sedative, antitussive, antiemetic.
Alimemazine is competitive with histamine at the histamine H1-receptors, thus it is anti-histamine H1, and antagonistic with most of pharmacological actions of histamine including urticaria, pruritus. Alimemazine is a sedative due to histamine N-methyltransferase enzyme inhibition and due to blocking central receptors secreting histamine and concomitantly acting on other receptors, especially serotoninergic receptor. Besides, alimemazine is antiemetic by a direct effect on chemical sensitive central area of spinal cord, maybe by blocking dopaminergic receptors at this area.
Alimemazine is rapidly absorbed by the gastrointestinal tract. After the drug is taken for 15 - 20 minutes, its effect lasts for 6 - 8 hours. Elimination half-life is 3.5 - 4 hrs; 20 - 30% is bound to plasma protein. Alimemazine is excreted by the kidneys as sulfoxide metabolites (70 - 80% after 48 hours).
Effects on works:
Patients should be warned about sedation and drowsiness during the treatment, and advised not to operate machinery, drive, work at height or other cases.
Alimemazine should be used with caution in elderly patients, particularly in very hot and cold weather (risk of hyper/hypothermia); elderly patients who are more susceptible to orthostatic hypotension; patients with certain cardiovascular diseases.
The drug is not indicated in pregnant women and nursing mothers.
The sedative effect of alimemazine may be intensified by alcohol, so alcohol should be avoided during the therapy.
Concomitant administration of alimemazine and barbituric agent and other sedatives has been reported to increase the effect of central nervous system inhibition, respiratory depression of alimemazine. The anticholinergic effect may be enhanced by other anticholinergic drugs. Some drugs interfere with absorption of alimemazine: antacids, anti-Parkinson and lithium.
Drowsiness, headache, lassitude, dizziness, dryness of mouth, increased viscidity of bronchial secretion, optical accommodation disorders, constipation, urinary retention.
Rarely: agranulocytosis, leukopenia, hypotension, tachycardia, cholestatic jaundice hepatitis, extrapyramidal symptom, Parkinson tremor, anxiety, acute dystonia, decrease in convulsion threshold in epilepsy.
Symptoms of overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmias and hypothermia. Extra-pyramidal reactions may occur.
Treatment of overdosage:
If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive in cardiovascular collapse, arrhythmias, severe central nervous inhibition.
Read the directions carefully before use.
For more information, please consult a physician.
Store in dry places, not exceeding 300C, protect from light.
/
Symptomatic treatment of various cases:
Respiratory allergies (rhinitis, sneezing, coryza) and skin rashes (urticaria, pruritus).
Dry cough (due to allergy or irritations).
Alimemazine tartrate may be used as a substitute for benzodiazepine in short-term treatment of insomnia.
Alimemazine should be avoided in patients known to be hypersensitive to any of the excipients or phenothiazines.
Alimemazine is contraindicated for use in children less than 2 years of age.
Alimemazine should be avoided in patients with hepatic or renal dysfunction, epilepsy, Parkinson's disease, hypothyroidism, myasthenia gravis, prostatic hypertrophy.
Alimemazine should not be used in patients with history of granulocytopenia, closed-angle glaucoma.
Short-term treatment of:
* Allergy and cough:
Adults: oral dose of 1 - 2 tablets x 2 - 4 times daily.
Children aged > 2 years: oral dose of 0.5 - 1 mg/ kg body-weight daily, in divided doses.
* Insomnia:
Adults: oral dose of 1 - 4 tablets, given before bedtime.
Children aged > 2 years: oral dose of 0.25 - 0.5 mg/ kg body-weight daily, given before bedtime.
Register an account - receive thousands of information
You will be one of the first to receive information, news, recruitment news... from Hau Giang Pharmaceutical as soon as possible. Register today to enjoy thousands of incentives from Hau Giang Pharmaceutical.
